BioRestorative Therapies is a life sciences company focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult stem cells. Co.'s cell therapy candidate, BRTX-100, is a product formulated from autologous (or person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. Co. is developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue. Co. has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The BRTX stock yearly return is shown above.
The yearly return on the BRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|